Facio Therapies B.V.

https://www.facio-therapies.com

Facio Therapies, established in 2014, is a Netherlands-based company with a single focus - to overcome FSHD by developing a causal therapy that restores the repression of toxic DUX4. Facio works with leaders in the field to develop an affordable and accessible causal therapy for as many people with FSHD and in the most expeditious fashion possible. Being by and for people with FSHD, the business approach is to have a positive impact on lives rather than maximize financial gain. Facio's founders - Kees van der Graaf (Netherlands), Bill Moss (Australia), and Neil Camarta (Canada) - are business leaders from the FSHD community. *

	Start	2014-01-01 established
	Industry	drug discovery
	Industry 2	drug development

	Region	Netherlands_oo
	Country	Netherlands
	Street	8 Galileiweg
	City	2333 BD Leiden
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2024-02-12

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Facio Therapies B.V.

[1] Evotec AG. (6/20/17). "Press Release: Evotec Announces Strategic Investment in Facio Therapies to Support Development of Novel FSHD Therapy". Hamburg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]